Send the following on WhatsApp
Continue to Chathttps://nl.marketscreener.com/koers/aandeel/IMMATICS-N-V-109287208/nieuws/Immatics-N-V-start-Fase-1-2-klinische-studie-om-Promame-TCR-Bispecific-IMA402-te-evalueren-bij-pati-44578694/?utm_source=whatsapp&utm_medium=social&utm_campaign=share